RecruitingPhase 2NCT07387471

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Studying Waldenström macroglobulinemia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AbbVie
Principal Investigator: ABBVIE INC.
AbbVie
Intervention: Venetoclax(drug)
Enrollment: 14 enrolled
Eligibility: 18 years · All sexes
Timeline: 2026 – 2028

Study locations (3)

NHO Mito Medical Center /ID# 279175, Higashiibaraki-gun, Ibaraki, Japan
National Cancer Center Hospital /ID# 279076, Chuo-Ku, Tokyo, Japan
National Hospital Organization Disaster Medical Center /ID# 277741, Tachikawa, Tokyo, Japan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07387471 on ClinicalTrials.gov

Other trials for Waldenström macroglobulinemia

Additional recruiting or active studies for the same condition.

See all trials for Waldenström macroglobulinemia →

← Back to all trials